Danaher’s Leica Biosystems to Acquire StatLab

Danaher operating company Leica Biosystems has begun a deal to acquire StatLab, a privately-held developer and manufacturer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity.

Established over 50 years ago, StatLab touts a portfolio of products for pre-analytical and analytical histology, ranging from specimen collection and tissue processing through slide preparation and staining. The company said it shares Leica’s drive to advance cancer diagnostics and improve outcomes, building on a reputation for quality, innovation, and customer partnership.

After the transaction has closed, StatLab will become part of Leica Biosystems.

Leica is a cancer diagnostics company with a suite of anatomic and digital pathology solutions. The company expects to close the deal for StatLab by the end of 2026 and did not disclose the acquisition’s financial terms.

Comment from Leica Biosystems executive

Perez Fernandez, group executive, Danaher’s Diagnostics business, and president, Leica Biosystems: “We are excited by the opportunity to combine StatLab’s trusted portfolio with Leica Biosystems’ global leadership in pathology, computational pathology and AI-enabled diagnostics. Together, we can solve some of the hardest problems in healthcare by helping laboratories achieve the consistency, standardization, and quality required to adopt AI-enabled cancer diagnostics at scale. We look forward to welcoming this talented team to Leica Biosystems. Every step we take to accelerate critical cancer diagnostics helps patients get on the path to treatment faster.”